Correction: Bishayee et al. Lotus (Nelumbo nucifera Gaertn.) and Its Bioactive Phytocompounds: A Tribute to Cancer Prevention and Intervention. Cancers 2022, 14, 529
Table Legend
Error in Table
Materials Tested | Animal Tumor Models | Anticancer Effects | Mechanisms | Dose (Route) | Duration | References |
---|---|---|---|---|---|---|
Breast cancer | ||||||
Flavonoid-rich leaf extract | BALB/c athymic nude mice injected with MCF-7 cells | Reduced tumor volume and weight | ↓HER2; p-HER2; ↓Fas | 0.5 & 1% (diet) | 28 days | Yang et al., 2011 [79] |
Aqueous leaf extract | MDA-MB-231 cells injected in female C57BL/6 nude mice | Inhibited tumor growth | Not reported | 0.5–2 % (s.c.) | 14 days | Chang et al., 2016 [80] |
Liensinine + doxorubicin | Female nude mice injected with MDA-MB-231 cells | Reduced tumor growth | ↑Apoptosis; ↑cleaved caspase-3; ↓autophagy/mitophagy; ↑auto-phagosome /mitophagosome; ↑colocalization of DNM1L and TOMM20 | 60 mg/kg (i.p.); 2 mg/kg (i.p.) | 30 days | Zhou et al., 2015 [90] |
Colon cancer | ||||||
Nuciferine | CT29 cells subcutaneously implanted in nude mice | Reduced tumor weight | Not reported | 9.5 mg/kg (i.p.) | 3 times a week for 3 weeks | Qi et al., 2016 [96] |
Liensinine | HT29 cells injected in female BALB/c nude mice | Suppressed colorectal tumorigenesis, reduced tumor size | ↓Ki-67 | 30 mg/kg (oral) | Every other day for 15 days | Wang et al., 2018 [97] |
Eye cancer | ||||||
Neferine | WERI-Rb-1 cells injected in female athymic nude mice | Reduced tumor volume and weight | ↓Ki-67; ↓VEGF; ↓SOD; ↑MDA | 0.5–2 mg/kg (i.p) | Every 3 days for 30 days | Wang et al., 2020 [100] |
Gallbladder cancer | ||||||
Liensinine | NOZ cells injected in BALB/c nude mice | Reduced tumor volume and weight | ↓Ki-67 | 2 mg/kg (i.p) | Every 2 days | Shen et al., 2019 [101] |
Gastric cancer | ||||||
Liensinine from seeds | SGC7901 cells injected in BALB/c homozygous (nu/nu) nude mice | Reduced tumor size | ↓Ki-67 | 10 µM (i.p.) | Every 2 days for a month | Yang et al., 2019 [106] |
Head and neck cancers | ||||||
Neferine | CAL27 cells injected in male BALB/c nude mice | Reduced tumor volume | ↑Apoptosis; ↑autophagy, ↑cleaved caspase-3, ↑cleaved PARP1, ↑LC3; ↑p62 | 10 mg/kg (i.p) | Not reported | Zhu et al., 2021 [107] |
Liver cancer | ||||||
Water-soluble polysaccharides from seeds | H22 cells injected in female Kunming mice | Reduced tumor weight | ↑TNF-ɑ; ↑IL-2; ↑SOD; ↓MDA | 50–200 mg/kg (oral) | 14 days | Zheng et al., 2016 [102] |
Leaf extract | DEN fed male Sprague-Dawley rats | Reduced tumor size | ↓AST; ↓ALT; ↓albumin; ↓total triglyceride; ↓total cholesterol; ↓lipid peroxidation; ↑GSH; ↑GSHPx; ↑SOD; ↑CAT; ↑GST; ↓Rac1; ↓PKCɑ; ↓TNF-ɑ; ↓IL-6 | 0.5–2.0% (p.o.) | 12 weeks | Horng et al., 2017 [119] |
Leaf extract | 2-AAF-induced male Wistar rats | Inhibited hepatic fibrosis and hepatocarcinogenesis | ↓Triglycerides; ↓total cholesterol; ↓AFP; ↓IL-6; ↓TNF-ɑ; ↓AST; ↓ALT; ↓γGT; ↓GST-Pi; ↓lipid peroxidation; ↓8-OHdG; ↑Nrf2; ↑CAT; ↑GPx; ↑SOD-1 | 0.5–2% in the diet (p.o.) | 6 months | Yang et al., 2019 [120] |
Neferine+oxaliplatin | HepG2 and Bel-7402 cells injected in male BALB/c mice | Increased tumor volume reducing the effect of oxaliplatin | ↑E-cadherin; ↓Vimentin; ↓Ki-67; | 20 mg/kg/d (i.p.) | 3 weeks | Deng et al., 2017 [116] |
Isoliensinine | Huh-7 cells injected in male athymic nude mice and H22 cells injected in Kunming mice | Reduced tumor volume | ↑caspase-3; ↓Bcl-2; ↓Bcl-xL; ↓MMP-9; ↓p65 phosphorylation | 3 and 10 mg/kg/d (i.p. and gavage) | 10 days; 3 weeks | Shu et al., 2015 [117] |
Isoliensinine | Huh-7 cells transfectants injected in male athymic nude mice | Reduced tumor growth | ↑Caspase-3 activity | 10 mg/kg/d (gavage) | 20 days | Shu et al., 2016 [118] |
Lung cancer | ||||||
Leaf extract and leaf polyphenol extract | 4T-1 metastatic tumor in the lung of BALB/c mice | Reduced metastasis and tumor weight | ↓PKCɑ activation | 0.25, 1% (p.o.) | 19 days | Wu et al., 2017 [81] |
Nuciferine | A549 cells injected in BALB/c mice | Reduced tumor size and weight | ↑Apoptosis; ↓Bcl-2; ↑Bax; ↓Wnt/β-catenin; ↑Axin | 50 mg/kg (i.p.) | 3 times a week for 20 days | Liu et al., 2015 [126] |
Neferine | DEN-induced lung carcinogenesis in albino male Wistar rats | Suppressed tumor growth | ↓ROS; ↓lipid peroxidation; ↓protein carbonyl; ↑GSH; ↑SOD; ↑GPx; ↑GST; ↑CAT; ↓glycoprotein components; ↑ATPase; ↑p53; ↑Bax; ↑caspase-9; ↑caspase-3; ↓Bcl-2; ↓COX-2; ↓NF-κB; ↓CYP2E1; ↓VEGF; ↓PI3K; ↓Akt; ↓mTOR | 10–20 mg/kg (oral) | 20 alternate days | Sivalingam et al., 2019 [127] |
Neural cancer | ||||||
Nuciferine | SY5Y cells subcutaneously implanted in nude mice | Reduced tumor weight | Not reported | 9.5 mg/kg (i.p.) | 3 times a week for 3 weeks | Qi et al., 2016 [96] |
Nuciferine | U251 cells subcutaneously inoculated in BALB/c nude mice | Suppressed tumor weight and size | ↓Ki-67; ↓CDC2; ↓Bcl-2; ↓HIF1A; ↓N-cadherin; ↓VEGFA | 15 mg/kg (i.p.) | Once a day for 2 weeks | Li et al., 2019 [130] |
Skin cancer | ||||||
Procyanidin extract from seedpod | B16 cells inoculated into syngeneic C57BL/6 J mice | Suppressed tumor volume and weight | ↓lipid peroxidation levels; ↑SOD; ↑CAT; ↑GSPx; ↑spleen and thymus index | 60–120 mg/kg (i.g.) | Every 2–3 days for 15 days | Duan et al., 2010 [137] |
Leaf extract | UV-radiation exposed female guinea pigs | Reversed UVB-induced epidermal hyperplasia and hyperpigmentation | ↓MITF; ↓tyrosinase; ↓TRP-1; ↓PKA; ↓ERK; ↓melanin | 1–2% (topical) | 2 weeks | Lai et al., 2020 [138] |
7-Hydroxy-dehydronuciferine | A375.S2 cells injected in BALB/c nu/nu female mice | Reduced tumor volume | Not reported | 20 mg/kg (i.p.) | Every 7 days for 28 days | Wu et al., 2015 [139] |
Reference
- Bishayee, A.; Patel, P.A.; Sharma, P.; Thoutireddy, S.; Das, N. Lotus (Nelumbo nucifera Gaertn.) and Its Bioactive Phytocompounds: A Tribute to Cancer Prevention and Intervention. Cancers 2022, 14, 529. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bishayee, A.; Patel, P.A.; Sharma, P.; Thoutireddy, S.; Das, N. Correction: Bishayee et al. Lotus (Nelumbo nucifera Gaertn.) and Its Bioactive Phytocompounds: A Tribute to Cancer Prevention and Intervention. Cancers 2022, 14, 529. Cancers 2022, 14, 2116. https://doi.org/10.3390/cancers14092116
Bishayee A, Patel PA, Sharma P, Thoutireddy S, Das N. Correction: Bishayee et al. Lotus (Nelumbo nucifera Gaertn.) and Its Bioactive Phytocompounds: A Tribute to Cancer Prevention and Intervention. Cancers 2022, 14, 529. Cancers. 2022; 14(9):2116. https://doi.org/10.3390/cancers14092116
Chicago/Turabian StyleBishayee, Anupam, Palak A. Patel, Priya Sharma, Shivani Thoutireddy, and Niranjan Das. 2022. "Correction: Bishayee et al. Lotus (Nelumbo nucifera Gaertn.) and Its Bioactive Phytocompounds: A Tribute to Cancer Prevention and Intervention. Cancers 2022, 14, 529" Cancers 14, no. 9: 2116. https://doi.org/10.3390/cancers14092116
APA StyleBishayee, A., Patel, P. A., Sharma, P., Thoutireddy, S., & Das, N. (2022). Correction: Bishayee et al. Lotus (Nelumbo nucifera Gaertn.) and Its Bioactive Phytocompounds: A Tribute to Cancer Prevention and Intervention. Cancers 2022, 14, 529. Cancers, 14(9), 2116. https://doi.org/10.3390/cancers14092116